Geriatric Unit, Department of Internal Medicine, University Hospital of Pisa, Via Roma 67, 56126-Pisa, Italy.
Mini Rev Med Chem. 2011 Aug;11(9):746-52. doi: 10.2174/138955711796355249.
Tyrosine kinase receptors have been shown to play an important role in epithelial thyroid tumor growth and angiogenesis. Thyroid cancers commonly present oncogene mutations involved in MAPK kinase pathway like BRAF and RET; they are also frequently dependent on VEGF stimuli. Preliminary clinical experiences suggest a promising role of sunitinib (a tyrosine kinase inhibitor) for the treatment of advanced thyroid cancers. This review deals with the available data on the effect of sunitinib in the treatment of metastatic, radioiodine refractory thyroid cancers. We also report our experience with the off-label use of sunitinib in such patients.
酪氨酸激酶受体在甲状腺上皮肿瘤的生长和血管生成中起着重要作用。甲状腺癌常表现为涉及 MAPK 激酶途径的致癌基因突变，如 BRAF 和 RET；它们通常也依赖于 VEGF 刺激。初步的临床经验表明舒尼替尼（一种酪氨酸激酶抑制剂）在治疗晚期甲状腺癌方面具有广阔的前景。这篇综述涉及舒尼替尼治疗转移性、放射性碘难治性甲状腺癌的疗效的现有数据。我们还报告了我们在这些患者中使用舒尼替尼的经验。
